SARASOTA, Fla., Jan. 5, 2015 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company
focused on chronic inflammatory disease and neurologic disorders,
announced that the Company's presentation at the Biotech Showcase™
2015, taking place in San Francisco,
CA, is scheduled for Monday, January
12th at 4:00PM PT
(7:00 PM ET) in the "Mission I" room
of the Parc 55 Wyndham in Union Square.
Michael Mullan, MBBS, PhD,
Chairman and CEO of Rock Creek Pharmaceuticals, will present
preclinical and clinical data for anatabine citrate, a small
molecule cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics. Dr. Mullan will outline the
Company's regulatory strategy and ongoing drug development
initiatives designed to advance its lead molecule into phase I and
phase II trials.
A live webcast of Dr. Mullan's Biotech Showcase presentation can
be accessed at the following URL:
http://edge.media-server.com/m/p/763wjx9w. An archived version
of the webcast will be available two hours following the
presentation and can be accessed within the investors'
section of the Rock Creek Pharmaceuticals website at
www.rockcreekpharmaceuticals.com
About Biotech Showcase 2015:
Co-produced by Demy-Colton Life Science Advisors and EBD Group,
Biotech Showcase is an investor and partnering conference devoted
to providing private and public biotechnology and life sciences
companies an opportunity to present to, and meet with, investors
and pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences. Now in
its seventh year, Biotech Showcase is expected to attract upwards
of 1,500 attendees. (http://www.ebdgroup.com/bts/index.php)
About Anatabine Citrate:
Rock Creek Pharmaceuticals' anatabine citrate is a small
molecule, cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics. The Company has sponsored
extensive pre-clinical (in vitro and in vivo) studies resulting in
peer reviewed and published scientific journal articles, covering
models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune
Thyroiditis. All these studies demonstrated the anti-inflammatory
effects of anatabine. In addition, the Company's compilation of
human exposure, safety and tolerability data, derived primarily
from human clinical studies and post-marketing data collection of
the previously marketed nutraceutical product, has provided
important insights for clinical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development
company focused on the discovery, development and commercialization
of new drugs, formulations and compounds that provide therapies for
chronic inflammatory disease, neurologic disorders and behavioral
health.
For more information, visit:
http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and approval of
anti-inflammatory drug candidates, the effect of any competitive
products, our ability to license and protect our intellectual
property, our ability to raise additional capital in the future
that is necessary to maintain our business, changes in government
policy and/or regulation, potential litigation by or against us,
any governmental review of our products or practices and the
outcome of the ongoing investigations as well as other risks
discussed from time to time in our filings with the Securities and
Exchange Commission, including, without limitation, our annual
report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed
on August 11, 2014. We undertake no
duty to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor
Relations
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharmaceuticals.com
Stephanie Carrington
Investors
Integrated Corporate Relations, Inc. (ICR): Redefining Strategic
Communications
685 Third Avenue, 2nd
Floor,
New York, NY 10017
(646) 277-1282
stephanie.carrington@icrinc.com
Logo -
http://photos.prnewswire.com/prnh/20150105/166900LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rock-creek-pharmaceuticals-to-webcast-presentation-at-the-biotech-showcase-2015-in-san-francisco-on-monday-january-12-at-400pm-pacific-300015509.html
SOURCE Rock Creek Pharmaceuticals, Inc.